What happened
Bio Search announced a share-exchange agreement to acquire InnerEye, integrating real-time EEG analysis into its healthcare AI portfolio.
On November 9, 2026, Japan-based Bio Search announced it had signed a share-exchange agreement to acquire 100% of InnerEye, an Israeli company specializing in AI that analyzes brain signals in real time. The transaction is structured to make InnerEye a wholly owned subsidiary of Bio Search, adding its expert-decision technology to Bio Search’s existing healthcare AI business.
The deal is not yet complete. Closing is subject to customary conditions, including approvals from relevant Israeli authorities, and is scheduled to occur between December 2026 and early January 2027. Until these conditions are met, the acquisition remains a signed agreement rather than a finalized corporate merger.
InnerEye, established in 2014 by Amir Geva and Leon Deouell, develops proprietary algorithms that interpret electroencephalogram (EEG) readings to distinguish cognitive states involved in perception and decision-making. Its product, Minded A.I., uses a device interface to transfer aspects of expert judgment into AI models, creating a feedback loop that improves both the models and the expert users.
For Bio Search, this acquisition adds real-time brain-signal algorithms to a business that already utilizes EEG, ECG, heart-rate, and EMG signals. The company plans to create a shared platform for pooling biological data to train AI models, targeting uses such as visualizing cognitive function, supporting early diagnosis, and industrial automation.
Why it matters
This acquisition combines biological sensing hardware with advanced brain-signal interpretation algorithms, aiming to create a unified platform for training AI models on expert decision-making. It represents a concrete step toward commercializing brain-computer interface technologies for healthcare and industrial applications, though the deal is not yet closed.
This transaction is significant because it merges hardware-based biological sensing with sophisticated software for interpreting neural data. By combining Bio Search’s device engineering capabilities with InnerEye’s real-time EEG analysis, the companies aim to build a more robust platform for training AI models on human expert decision-making.
The integration targets practical applications in healthcare and industry, including early diagnosis and decision support. This moves brain-AI technology from research concepts toward commercial deployment, although Bio Search has not quantified the expected improvements in or .
The deal also has strategic implications for Bio Search’s corporate roadmap, which includes a target of a Nasdaq listing in 2028. The successful integration of InnerEye’s technology will serve as a concrete operational test for this expansion plan, demonstrating the viability of their combined brain-AI offerings to potential investors.
Interactive Mechanism: How It Actually Works
Explore the underlying technology behind this development interactively.
Which component of an AI application is the machine-learning model itself?
What to watch next
Regulatory approvals in Israel and the final closing of the transaction, as well as the integration of InnerEye’s algorithms into Bio Search’s existing hardware.
The immediate next step is the receipt of regulatory approvals from Israeli authorities, which are required for the transaction to close. The deal is expected to finalize between December 2026 and early January 2027.
Investors and industry observers should monitor the technical integration of InnerEye’s algorithms with Bio Search’s existing hardware. The success of the shared data platform for training AI models will be a key indicator of the partnership’s value.
The progress toward Bio Search’s 2028 Nasdaq listing target will also be a relevant metric, as the acquisition is a central part of their expansion strategy into global commercial scale for brain-AI technology.